

MAYO CLINIC UPDATE

14-15 June 2024 - Oporto

AUDITORIUM
SUPER BOCK ARENA

SERVIÇO DE NEFROLOGIA
IPOPORTO



PRELIMINARY PROGRAM & SPEAKERS

Complement-mediated Thrombotic Microangiopathy (CM-TMA) / Atypical Hemolytic Syndrome

Ann M. Moyer, M.D., Ph.D.

Lupus Nephritis (What's new?)

Ali Duarte Garcia, M.D., PhD.

ANCA Vasculitis: Novel, more effective and safer treatment modalities

Ulrich Specks, M.D.,P.I.

ANCA Vasculitis – Towards personalized medicine

Marta Casal Moura, M.D., Ph.D.

Diagnosis and treatment of Membranous Nephropathy

Fernando Fervenza, M.D., Ph.D.

New antigens in Membranous Nephropathy

Fernando Fervenza, M.D., Ph.D.

An update on the classification and diagnosis of Monoclonal Gammopathy of Renal Significance lesions

Samih Nasr, M.D.

Current approaches in treatment of Monoclonal Gammopathy of Renal Significance

Ladan Zand, M.D.

Genetics and Kidney Diseases

Filippo Pinto e Vairo, M.D., Ph.D.

Autosomal Dominant Polycystic Kidney Disease in 2024

Vicente Torres, M.D., Ph.D.

SGLT2 Inhibitors and the Kidney

Maria José Soler, M.D., Ph.D.

MAYO CLINIC UPDATE

14-15 June 2024 - Porto

AUDITORIUM
SUPER BOCK ARENA

SERVIÇO DE NEFROLOGIA
IPO PORTO



Renal Disease in Pregnancy

Vesna Garovic, M.D., Ph.D.

Artificial Intelligence to guide management of Acute Kidney Injury

Kianoush Kashani, M.D., M.S.

New drugs and perspectives for the treatment of Kidney Diseases in 2024

Emilio Sánchez, M.D, Ph.D.

Onco-nephrology

Sandra Herrmann M.D. and Department of Onco-nephrology of IPO - Porto

- Chimeric antigen receptor therapy (CAR) – T Cell Therapy and other targeted cancer therapy
- CAR – T cells and the Kidney
- Immune Checkpoint inhibitors
- Mult'iTox Consultation: A multidisciplinary approach to optimize the immune effects of checkpoint inhibitors

Clinical Pathology cases: chosen among the submitted abstracts

2 sessions of 4 clinical cases (1 session per day)

Sanjeev Sethi, Fernando Fervenza, José Maximino